Evidence map›Paper›PMID 28409011›Full record

ArticleOpen heart

Utility of T-wave amplitude as a non-invasive risk marker of sudden cardiac death in hypertrophic cardiomyopathy.

Alan Sugrue, Ammar M Killu, Christopher V DeSimone, Anwar A Chahal, Josh C Vogt, Vaclav Kremen, JoJo Hai, David O Hodge, Nancy G Acker, Jeffrey B Geske and 5 more

Open access · goldAbstract read
In one paragraph

Article in Open heart. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Alan SugrueDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Ammar M KilluDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Christopher V DeSimoneDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Anwar A ChahalCardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Josh C VogtDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Vaclav KremenDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
JoJo HaiDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
David O HodgeDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Nancy G AckerDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Jeffrey B GeskeDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Michael J AckermanDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Steve R OmmenDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Grace LinDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Peter A NoseworthyDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Peter A BradyDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USUniversity College London · GBUniversity of Minnesota Rochester · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
CARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7M
NCATS NIH HHS UL1 TR000135NHLBI NIH HHS T32 HL007111
6 · The paper itself

Abstract

objectiveSudden cardiac arrest (SCA) is the most devastating outcome in hypertrophic cardiomyopathy (HCM). We evaluated repolarisation features on the surface electrocardiogram (ECG) to identify the potential risk factors for SCA.

methodsData was collected from 52 patients with HCM who underwent implantable cardioverter defibrillator (ICD) implantation. Leads V2 and V5 from the ECG closest to the time of ICD implant were utilised for measuring the Tpeak-Tend interval (Tpe), QTc, Tpe/QTc, T-wave duration and T-wave amplitude. The presence of the five traditional SCA-associated risk factors was assessed, as well as the HCM risk-SCD score.

results16 (30%) patients experienced aborted cardiac arrest over 8.5±4.1 years, with 9 receiving an ICD shock and 7 receiving ATP. On univariate analysis, T-wave amplitude was associated with appropriate ICD therapy (HR per 0.1 mV 0.79, 95% CI 0.56 to 0.96, p=0.02). Aborted SCA was not associated with a greater mean QTc duration, Tpeak-Tend interval, T-wave duration, or Tpe/QT ratio. Multivariate analysis (adjusting for cardinal HCM SCA-risk factors) showed T-wave amplitude in Lead V2 was an independent predictor of risk (adjusted HR per 0.1 mV 0.74, 95% CI 0.57 to 0.97, p=0.03). Addition of T-wave amplitude in Lead V2 to the traditional risk factors resulted in significant improvement in risk stratification (C-statistic from 0.65 to 0.75) but did not improve the performance of the HCM SCD-risk score.

conclusionsT-wave amplitude is a novel marker of SCA in this high risk HCM population and may provide incremental predictive value to established risk factors. Further work is needed to define the role of repolarisation abnormalities in predicting SCA in HCM.

Indexed as

T wave

Identifiers

PMID28409011
PMCPMC5384475
OpenAlexW2590622060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.